

Paper alert

387 James Melville, Peter Norman & David P Rotella

Patent alert

400 Thomson Scientific Current Awareness Analysts

Web alert

410 David Cavalla

The Chemistry of Drug Design and Lead Optimization

Edited by William J Greenlee & Manoj Desai

412 William J Greenlee & Manoj Desai

Editorial overview: Backup programs in drug discovery

414 David Brown

Editorial opinion: Target selection and pharma industry productivity: What can we learn from technology S-curve theory?

419 Nathan Brown & Richard A Lewis

Exploiting QSAR methods in lead optimization

425 Paul J Edwards, Brigitte Allart, Martin JI Andrews, J Andrew Clase & Christel Menet

Expediting drug discovery: Recent advances in fast medicinal chemistry – optimization of hits and leads

445 Lars Ole Haustedt, Christian Mang, Karsten Siems & Hajo Schiewe

Rational approaches to natural-product-based drug design

463 Chaohong Sun & Philip J Hajduk

NMR in target profiling and compound file enhancement

471 John O Link & Sheila Zipfel

Advances in cathepsin S inhibitor design

483 Martin J Drysdale, Paul A Brough, Andrew Massey, Michael Rugaard Jensen & Joseph Schoepfer

Targeting Hsp90 for the treatment of cancer

496 Mark D McBriar

Recent advances in the discovery of melanin-concentrating hormone receptor antagonists

509 Hongyu Zhao & Gang Liu

Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question

516 George V De Lucca

Recent developments in CCR3 antagonists